Evommune Inc (EVMN) Stock Price, Quote & News

Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Industry: Biotechnology

Sector: Healthcare

Phone: (925) 247-4481

Website: www.evommune.com

Address:

1891 Page Mill Road, Palo Alto, United States

JRshocker Jul. 30 at 3:18 PM

$EVMN is anyone here?

1 · Reply

SevenPhigs27 Jul. 22 at 7:23 PM

$EVMN Took a starter. GLTA

0 · Reply

elmono Jul. 14 at 11:12 PM

$EVMN ageing nicely. Shkreli nice contrarian indicator

0 · Reply

fda_tracker Jul. 14 at 2:54 PM

$EVMN Phase 2 trial w/est Jul completion date NCT07150845: https://www.clinicaltrials.gov/study/NCT07150845 Trial Tracker: https://www.fdatracker.com/trial-tracker/

0 · Reply

FilingTracker Jul. 9 at 12:01 AM

$EVMN Insider bought the dip: https://filingtracker.ai/filing/2044725/0001290976-26-000004

0 · Reply

Market_Pulse_Report Jul. 6 at 12:34 AM

$EVMN

0 · Reply

Market_Pulse_Report Jul. 4 at 6:09 PM

$EVMN Check out this great informative video on this company tons of info https://youtu.be/PRNOWUopqig?si=IHiaYq4otfM9aRJT

0 · Reply

Robby83 Jul. 2 at 4:24 PM

$EVMN well back down to my entry... lots of selling pressure breaking my chart setup

0 · Reply

Timefortendies77 Jul. 1 at 9:00 PM

$CLDX got a bit of extra hype on the Russel 2000 and then the $EVMN crash. We are undisputed #1 for mast cell diseases right now and first to market if all goes well.

0 · Reply

Tradr1205 Jul. 1 at 2:52 PM

$EVMN Just loaded up!!

0 · Reply

Evommune initiates Phase 2b trial of EVO756

Jul 30, 2026, 8:00 AM EDT - 5 days ago

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

2026-07-29T20:28:13.000Z - 5 days ago

Evommune participates in a conference call with Cantor

2026-07-16T14:00:18.000Z - 19 days ago

Clear Street sees attractive point into Evommune after selloff

2026-07-01T10:50:37.000Z - 4 weeks ago

Septerna price target lowered to $45 from $52 at Guggenheim

SEPN

2026-06-30T11:00:29.000Z - 5 weeks ago

Evommune price target lowered to $26 from $55 at Morgan Stanley

2026-06-30T10:05:57.000Z - 5 weeks ago

Evommune downgraded to Neutral from Buy at H.C. Wainwright

2026-06-29T20:20:55.000Z - 5 weeks ago

Evommune price target lowered to $28 from $53 at Clear Street

2026-06-29T13:40:41.000Z - 5 weeks ago

Evommune downgraded to Market Perform from Outperform at William Blair

2026-06-29T12:35:45.000Z - 5 weeks ago

Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint

Jun 29, 2026, 8:30 AM EDT - 5 weeks ago

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

2026-06-22T21:55:09.000Z - 6 weeks ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

ABBV APGE

Jun 2, 2026, 11:30 AM EDT - 2 months ago

Evommune Transcript: AGM 2026

2026-05-11T15:52:55.000Z - 3 months ago

Evommune price target raised to $55 from $54 at Morgan Stanley

2026-05-07T22:50:50.000Z - 3 months ago

Evommune reports Q1 EPS (64c), consensus (71c)

May 7, 2026, 4:05 PM EDT - 3 months ago

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 7, 2026, 7:00 AM EDT - 3 months ago

Evommune Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Evommune Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Evommune Slides: Corporate presentation

2026-04-30T20:39:05.000Z - 3 months ago

Evommune initiated with a Buy at Stifel

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Evommune Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Evommune Registration statement: Registration filing

Apr 13, 2026, 2:00 PM EDT - 4 months ago

Evommune Transcript: Status update

2026-04-07T14:18:01.000Z - 4 months ago

Evommune assumed with an Outperform at Oppenheimer

Apr 6, 2026, 9:00 AM EDT - 4 months ago

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

2026-03-18T10:12:14.000Z - 4 months ago

Evommune price target lowered to $50 from $65 at H.C. Wainwright

Mar 5, 2026, 4:01 PM EST - 5 months ago

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Mar 5, 2026, 7:00 AM EST - 5 months ago

Evommune Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 5 months ago

Evommune Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 5 months ago

Evommune Slides: Corporate presentation

Feb 12, 2026, 8:30 PM EST - 6 months ago

Evommune Announces $125 Million Private Placement

Feb 10, 2026, 8:30 AM EST - 6 months ago

Evommune Transcript: Study result

Feb 10, 2026, 8:30 AM EST - 6 months ago

Evommune Press release: Study result

Feb 10, 2026, 8:30 AM EST - 6 months ago

Evommune Slides: Study result

Feb 10, 2026, 7:30 AM EST - 6 months ago

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Jan 7, 2026, 7:00 AM EST - 7 months ago

Evommune Slides: Corporate presentation

Dec 11, 2025, 4:05 PM EST - 8 months ago

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Dec 11, 2025, 4:00 PM EST - 8 months ago

Evommune Quarterly report: Q3 2025

Dec 11, 2025, 4:00 PM EST - 8 months ago

Evommune Earnings release: Q3 2025

Dec 11, 2025, 4:00 PM EST - 8 months ago

Evommune Slides: Corporate Presentation

Nov 5, 2025, 7:45 PM EST - 9 months ago

Evommune Announces Pricing of its Initial Public Offering

Oct 30, 2025, 6:30 AM EDT - 9 months ago

Evommune Announces Commencement of Initial Public Offering

Oct 17, 2025, 8:00 AM EDT - 10 months ago

Evommune Registration statement: Registration Filing

Oct 10, 2025, 8:31 AM EDT - 10 months ago

Evommune files for IPO to advance immune drug work

Oct 9, 2025, 2:18 PM EDT - 10 months ago

Evommune IPO Registration Document (S-1)

Oct 9, 2025, 10:32 AM EDT - 10 months ago

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

JRshocker Jul. 30 at 3:18 PM

$EVMN is anyone here?

1 · Reply

SevenPhigs27 Jul. 22 at 7:23 PM

$EVMN Took a starter. GLTA

0 · Reply

elmono Jul. 14 at 11:12 PM

$EVMN ageing nicely. Shkreli nice contrarian indicator

0 · Reply

fda_tracker Jul. 14 at 2:54 PM

$EVMN Phase 2 trial w/est Jul completion date NCT07150845: https://www.clinicaltrials.gov/study/NCT07150845 Trial Tracker: https://www.fdatracker.com/trial-tracker/

0 · Reply

FilingTracker Jul. 9 at 12:01 AM

$EVMN Insider bought the dip: https://filingtracker.ai/filing/2044725/0001290976-26-000004

0 · Reply

Market_Pulse_Report Jul. 6 at 12:34 AM

$EVMN

0 · Reply

Market_Pulse_Report Jul. 4 at 6:09 PM

$EVMN Check out this great informative video on this company tons of info https://youtu.be/PRNOWUopqig?si=IHiaYq4otfM9aRJT

0 · Reply

Robby83 Jul. 2 at 4:24 PM

$EVMN well back down to my entry... lots of selling pressure breaking my chart setup

0 · Reply

Timefortendies77 Jul. 1 at 9:00 PM

$CLDX got a bit of extra hype on the Russel 2000 and then the $EVMN crash. We are undisputed #1 for mast cell diseases right now and first to market if all goes well.

0 · Reply

Tradr1205 Jul. 1 at 2:52 PM

$EVMN Just loaded up!!

0 · Reply

HenrikTheBandit Jul. 1 at 2:23 PM

$EVMN averaged out, put it all in $CELH

0 · Reply

changf Jul. 1 at 11:57 AM

$EVMN I just buy it at $13.5。

0 · Reply

MarketPulsee Jun. 30 at 10:18 PM

$EVMN Morgan Stanley lowered Evommune’s price target to $26 from $55, while maintaining an Overweight rating. HC Wainwright downgraded the stock to Neutral from Buy following a clinical trial failure. Analysts noted that the investment thesis is now weakened, as the stock is no longer supported by two previously credible mid-stage mechanisms, significantly reducing visibility on the pipeline.

0 · Reply